Chimerix turns $39m into $935m
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
Chimerix's cancer transformation
US approval could mark the company's graduation to oncology.
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
US approval could mark the company's graduation to oncology.
